| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
None. DMPC is an excipient that forms lipid bilayers, suitable as a membrane model. It interacts with membrane proteins (e.g., GPCRs, ion channels), helping to maintain their native conformation in reconstituted systems.
|
|---|---|
| ln Vitro |
DMPC forms stable, well-characterized liposomes and supported lipid bilayers for biophysical and drug delivery studies. The addition of DMPC can enhance the constancy and in vitro antiproliferative effect of the anticancer agent carmofur. DMPC liposomes have been used to encapsulate both hydrophilic and lipophilic drugs, demonstrating controlled release properties.
|
| ln Vivo |
DMPC liposomes are biocompatible and biodegradable. In animal models, DMPC-containing formulations have been evaluated for drug delivery applications. For carmofur delivery, DMPC enhances the drug's stability and efficacy in vivo (reference; no detailed data provided). DMPC is widely used as a non-toxic excipient in liposomal drug products due to its favorable safety profile.
|
| Enzyme Assay |
DMPC is dissolved in chloroform or ethanol and mixed with other lipids (e.g., cholesterol, DOPC, DSPC). The lipid mixture is dried under nitrogen to form a thin film, which is hydrated with aqueous buffer (PBS, HEPES, 10 mM, pH 7.4) at a temperature above the Tm (>30degC). Multilamellar vesicles (MLVs) are formed, which are then extruded through polycarbonate membranes (50-200 nm pores) to produce large unilamellar vesicles (LUVs). Particle size, polydispersity index (PdI), zeta potential, and encapsulation efficiency are characterized by DLS, fluorescence assays, and cryo-TEM.
|
| Cell Assay |
DMPC liposomes are diluted in serum-free or complete medium. Cells (e.g., HeLa, HEK293, RAW264.7) are seeded in 96- or 24-well plates (1-5×10⁴ cells/well) and treated with DMPC liposomes (0.1-5 mg/mL total lipid) for 2-48 h. Cellular uptake is assessed by labeling liposomes with fluorescent lipids (e.g., Rhodamine-DMPE, NBD-PC) and measuring by flow cytometry or confocal microscopy. Cytotoxicity is evaluated by MTT or LDH assays. DMPC typically shows no significant toxicity at tested concentrations (cell viability >90%).
|
| Animal Protocol |
DMPC formulations are administered to mice or rats via intravenous (tail vein), intraperitoneal, or subcutaneous routes at lipid doses of 10-100 mg/kg. For biodistribution studies, tissues (liver, spleen, kidney, lung) are harvested at 1, 4, 24, and 48 h post-dose. Liposome content is quantified by HPLC or LC-MS/MS for encapsulated drugs, or by fluorescence for labeled lipids. Drug release and efficacy are evaluated by measuring drug concentration in plasma and tissues or by assessing therapeutic outcomes (e.g., tumor volume).
|
| ADME/Pharmacokinetics |
DMPC, as an endogenous-like phospholipid, is metabolized by phospholipase A2 and other lipid-metabolizing enzymes. Following i.v. administration, DMPC liposomes have a circulation half-life of 2-4 h for conventional (non-PEGylated) formulations. DMPC is rapidly cleared by the mononuclear phagocyte system (MPS), primarily in the liver (∼60-80% of dose) and spleen (∼10-20%). DMPC itself does not have a prolonged presence in plasma; its fatty acids are released and enter metabolic pathways.
|
| Toxicity/Toxicokinetics |
DMPC is widely considered safe and non-toxic. It is a naturally occurring phospholipid, and its degradation products are endogenous. In vitro, DMPC liposomes show no significant cytotoxicity up to 5 mg/mL. In vivo, single i.v. doses up to 200 mg/kg are well-tolerated in rodents, with no overt signs of toxicity (e.g., no changes in body weight, behavior, or serum biomarkers). DMPC is generally recognized as safe (GRAS) and is used in FDA-approved liposomal products.
|
| References | |
| Additional Infomation |
1,2-Di-O-myristoyl-sn-glycerol-3-phosphate choline is a 1,2-diacyl-sn-glycerol-3-phosphate choline in which the two phosphatidyl groups are designated as tetradecanoyl (myristoyl). It is an antigen and mouse metabolite. It is a 1,2-diacyl-sn-glycerol-3-phosphate choline, phosphatidylcholine 28:0, and tetradecanoate. Dimyristoyl lecithin is a myristylated phosphatidylcholine and a synthetic phospholipid used in liposomes and lipid bilayers with drug delivery properties. A synthetic phospholipid used in liposomes and lipid bilayers for research on biological membranes. See also: Dimyristoyl phosphatidylcholine (note moved to).
DMPC (CAS 18194-24-6, C3₆H₇2NO₈P, MW 677.9) has >97% purity and is a white crystalline powder. DMPC is used as an excipient in pharmaceutical formulations and as a model membrane in biophysical research. Storage at -20degC is required. DMPC is not a drug candidate; it is a research-grade excipient. No direct clinical use beyond its role in approved liposomal formulations has been reported. |
| Molecular Formula |
C36H72NO8P
|
|---|---|
| Molecular Weight |
677.93
|
| Exact Mass |
677.499
|
| CAS # |
18194-24-6
|
| Related CAS # |
1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d58;326495-29-8;1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d4;185906-01-8;1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d9;71479-88-4;1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d13;326495-28-7;1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d63;326495-30-1;1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d67;326495-32-3;(Rac)-1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d72;100483-63-4
|
| PubChem CID |
5459377
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
> 300ºC
|
| Melting Point |
130ºC to 139ºC
|
| LogP |
8.75
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
36
|
| Heavy Atom Count |
46
|
| Complexity |
765
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC
|
| InChi Key |
CITHEXJVPOWHKC-UUWRZZSWSA-N
|
| InChi Code |
InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-21-19-17-15-13-11-9-7-2/h34H,6-33H2,1-5H3/t34-/m1/s1
|
| Chemical Name |
[(2R)-2,3-di(tetradecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 50 mg/mL (73.75 mM)
DMSO: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (7.38 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (7.38 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (7.38 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4751 mL | 7.3754 mL | 14.7508 mL | |
| 5 mM | 0.2950 mL | 1.4751 mL | 2.9502 mL | |
| 10 mM | 0.1475 mL | 0.7375 mL | 1.4751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
